XORTX Therapeutics Inc. filed a 6-K report on March 26, 2026, indicating compliance with the Securities Exchange Act and confirming it will file under Form 20-F. This filing is categorized under 'Other Special Situation' and holds a neutral sentiment with no significant impact reported for investors.